BCR: a new target in resistance mediated by BCR/ABL-315I?

Targeting BCR/ABL with Tyrosine kinase inhibitors (TKIs) is a proven concept for the treatment of Philadelphia chromosome-positive (Ph+) leukemias but the “gatekeeper” mutation T315I confers resistance against all approved TKIs, with the only exception of ponatinib, a multi-targeted kinase inhibitor...

全面介紹

Na minha lista:
書目詳細資料
發表在:Genes Cancer
Main Authors: Haberbosch, Isabella, Rafiei, Anahita, Oancea, Claudia, Ottmann, Gerhart Oliver, Ruthardt, Martin, Mian, Afsar Ali
格式: Artigo
語言:Inglês
出版: Impact Journals LLC 2016
主題:
Research Paper
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4773704/
https://ncbi.nlm.nih.gov/pubmed/27014420
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍